ÂÜÀòÂÒÂ×

Hans-Georg Lerchen, Ph.D. is the Chief Scientific Officer of Vincerx. Before joining Vincerx, Dr. Lerchen was a Distinguished Fellow in the Bayer Science Fellow Network of the Pharmaceuticals R&D organization of Bayer AG. With 33 years background in medicinal chemistry, he is author or coauthor of 81 patents/patent applications and 27 peer reviewed publications. Dr. Lerchen contributed to 5 INDs and to the identification of numerous preclinical candidates and lead structures. With his research focus on prodrugs and drug delivery modalities, he was the medicinal chemistry lead and key driver of diverse bioconjugate programs, including the development of ADCs with the novel KSPi toxophore and legumain linker platform, which Vincerx acquired from Bayer. Dr. Lerchen received his Ph.D. in organic chemistry from the University of Mainz with Professor Horst Kunz. After a year of research as a Max Planck postdoctoral scholarship holder at the MPI for Biochemistry in Munich, he started his industrial career at Bayer AG Leverkusen in the Central Research Department. After 14 years with responsibilities for different basic research programs he moved to the Medicinal Chemistry unit of the Pharmaceuticals Division of Bayer in Wuppertal. As a renowned scientist in the ADC field, Dr. Lerchen is an invited speaker on various international conferences. He serves as a board member of the biochemistry subgroup of the German Chemical Society (GDCh).